Long-term effects of neonatal hydrocortisone treatment for chronic lung disease on the developing brain and heart

Seminars in Fetal and Neonatal Medicine

Volumn 14, Issue 3, 2009, Pages 171-177

  Rademaker, Karin J ^a   de Vries, Willem B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular effects; Chronic lung disease; Dexamethasone; Hydrocortisone; Neurodevelopmental outcome; Preterm

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE; PLACEBO;

ARTICLE; BRAIN; CARDIOMYOPATHY; CARDIOVASCULAR EFFECT; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEART; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART STRESS; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MEDICAL LITERATURE; MOTOR SYSTEM; NERVE CELL DIFFERENTIATION; NEWBORN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; THERAPY EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; CHILD DEVELOPMENT; CHRONIC DISEASE; DEXAMETHASONE; GLUCOCORTICOIDS; HEART; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT, NEWBORN; LUNG DISEASES; PITUITARY-ADRENAL SYSTEM;

EID: 63149189139     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2008.11.004     Document Type: Article

References (73)

1. Kinsella J.P., Greenough A., and Abman S.H. Bronchopulmonary dysplasia. Lancet 367 (2006) 1421-1431
2. Ramanathan R. Optimal ventilatory strategies and surfactant to protect the preterm lungs. Neonatology 93 (2008) 302-308
3. Mammel M.C., Green T.P., Johnson D.E., and Thompson T.R. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1 (1983) 1356-1358
4. Hack M., and Fanaroff A.A. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev 53 (1999) 193-218
5. Yeh T.F., Lin Y.J., Huang C.C., et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 101 (1998) E7
6. Shinwell E.S., Karplus M., Reich D., et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 83 (2000) F177-F181
7. O'Shea T.M., Kothadia J.M., Klinepeter K.L., et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 104 (1999) 15-21
8. Shinwell E.S., Karplus M., Bader D., et al. Neonatologists are using much less dexamethasone. Arch Dis Child Fetal Neonatal Ed 88 (2003) F432-F433
9. Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109 (2002) 330-338
10. Finer N.N., Powers R.J., Ou C.H., Durand D., Wirtschafter D., and Gould J.B. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics 117 (2006) 704-713
11. Short E.J., Klein N.K., Lewis B.A., et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 112 (2003) e359
12. Yeh T.F., Lin Y.J., Lin H.C., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350 (2004) 1304-1313
13. Parikh N.A., Lasky R.E., Kennedy K.A., et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 119 (2007) 265-272
14. Buimer M., van Wassenaer A.G., and Kok J.H. Postnatal administration of dexamethasone for weaning off the ventilator affects thyroid function. Neonatology 94 (2008) 164-169
15. Barker D.J. Fetal nutrition and cardiovascular disease in later life. Br Med Bull 53 (1997) 96-108
16. Doyle L.W., Faber B., Callanan C., and Morley R. Blood pressure in late adolescence and very low birth weight. Pediatrics 111 (2003) 252-257
17. Gluckman P.D., Cutfield W., Hofman P., and Hanson M.A. The fetal, neonatal, and infant environments - the long-term consequences for disease risk. Early Hum Dev 81 (2005) 51-59
18. Hanson M.A., and Gluckman P.D. Developmental processes and the induction of cardiovascular function: conceptual aspects. J Physiol 565 (2005) 27-34
19. Gillman M.W. Developmental origins of health and disease. N Engl J Med 353 (2005) 1848-1850
20. Andre P., Thebaud B., Odievre M.H., et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med 26 (2000) 1496-1500
21. Grier D.G., and Halliday H.L. Management of bronchopulmonary dysplasia in infants: guidelines for corticosteroid use. Drugs 65 (2005) 15-29
22. Eventov-Friedman S., and Shinwell E. Current controversies in perinatal steroid therapy. Acta Paediatr (2008) [Epub ahead of print]
23. Ng P.C., Lee C.H., Bnur F.L., et al. A double-blind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 117 (2006) 367-375
24. Seri I. Hydrocortisone and vasopressor-resistant shock in preterm neonates. Pediatrics 117 (2006) 516-518
25. Aucott S.W. Hypotension in the newborn: who needs hydrocortisone?. J Perinatol 25 (2005) 77-78
26. Lattimore K.A., Vazquez D.M., Barks J.D., and Bhatt-Mehta V. 12 month developmental outcome in infants treated with hydrocortisone for hydrocortisone for refractory hypotension. SPR (2007) E-PAS2007: 7934
27. Baden M., Bauer C.R., Colle E., Klein G., Taeusch Jr. H.W., and Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 50 (1972) 526-534
28. Watterberg K.L., Gerdes J.S., Gifford K.L., and Lin H.M. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 104 (1999) 1258-1263
29. Heide-Jalving M., Kamphuis P.J., van der Laan M.J., et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone?. Acta Paediatr 92 (2003) 827-835
30. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114 (2004) 1649-1657
31. Peltoniemi O., Kari M.A., Heinonen K., et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 146 (2005) 632-637
32. Bonsante F., Latorre G., Iacobelli S., et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 91 (2007) 217-221
33. Fitzhardinge P.M., Eisen A., Lejtenyi C., Metrakos K., and Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics 53 (1974) 877-883
34. Watterberg K.L., Shaffer M.L., Mishefske M.J., et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 120 (2007) 40-48
35. Lodygensky G.A., Rademaker K., Zimine S., et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 116 (2005) 1-7
36. Rademaker K.J., Rijpert M., Uiterwaal C.S., et al. Neonatal hydrocortisone treatment related to 1H-MRS of the hippocampus and short-term memory at school age in preterm born children. Pediatr Res 59 (2006) 309-313
37. Rademaker K.J., Uiterwaal C.S., Groenendaal F., et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 150 (2007) 351-357
38. Karemaker R., Heijnen C.J., Veen S., et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res 60 (2006) 745-750
39. Karemaker R., Kavelaars A., ter Wolbeek M., et al. Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age. Pediatrics 121 (2008) e870-e878
40. Sicard R.E., and Werner J.C. Dexamethasone induces a transient relative cardiomegaly in neonatal rats. Pediatr Res 31 (1992) 359-363
41. La Mear N.S., MacGilvray S.S., and Myers T.F. Dexamethasone-induced myocardial hypertrophy in neonatal rats. Biol Neonate 72 (1997) 175-180
42. de Vries W.B., Bal M.P., Homoet-van der Kraak P., et al. Suppression of physiological cardiomyocyte proliferation in the rat pup after neonatal glucocorticosteroid treatment. Basic Res Cardiol 101 (2006) 36-42
43. Bal M.P., de Vries W.B., van der Leij F.R., et al. Neonatal glucocorticosteroid treatment causes systolic dysfunction and compensatory dilation in early life: studies in 4-week-old prepubertal rats. Pediatr Res 58 (2005) 46-52
44. de Vries W.B., van der Leij F.R., Bakker J.M., et al. Alterations in adult rat heart after neonatal dexamethasone therapy. Pediatr Res 52 (2002) 900-906
45. Kamphuis P.J., de Vries W.B., Bakker J.M., et al. Reduced life expectancy in rats after neonatal dexamethasone treatment. Pediatr Res 61 (2007) 72-76
46. de Vries W.B., Hakim S., Bal M.P., et al. Unlike dexamethasone, neonatal hydrocortisone does not induce histopathological changes in the adult rat heart. SPR (2007) E-PAS2007: 5896
47. Werner J.C., Sicard R.E., Hansen T.W., Solomon E., Cowett R.M., and Oh W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 120 (1992) 286-291
48. Israel B.A., Sherman F.S., and Guthrie R.D. Hypertrophic cardiomyopathy associated with dexamethasone therapy for chronic lung disease in preterm infants. Am J Perinatol 10 (1993) 307-310
49. Bensky A.S., Kothadia J.M., and Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics 97 (1996) 818-821
50. Evans N. Cardiovascular effects of dexamethasone in the preterm infant. Arch Dis Child Fetal Neonatal Ed 70 (1994) F25-F30
51. Smets K., and Vanhaesebrouck P. Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease. Eur J Pediatr 155 (1996) 573-575
52. Durand M., Sardesai S., and McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics 95 (1995) 584-590
53. Gill A.W., Warner G., and Bull L. Iatrogenic neonatal hypertrophic cardiomyopathy. Pediatr Cardiol 17 (1996) 335-339
54. Riede F.T., Schulze E., Vogt L., and Schramm D. Irreversible cardiac changes after dexamethasone treatment for bronchopulmonary dysplasia. Pediatr Cardiol 22 (2001) 363-364
55. Mieskonen S., Eronen M., Malmberg L.P., Turpeinen M., Kari M.A., and Hallman M. Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year follow-up of cardiopulmonary function and growth. Acta Paediatr 92 (2003) 896-904
56. Jones R.A. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. Pediatrics 116 (2005) 379-384
57. Wilson T.T., Waters L., Patterson C.C., et al. Neurodevelopmental and respiratory follow-up results at 7 years for children from the United Kingdom and Ireland enrolled in a randomized trial of early and late postnatal corticosteroid treatment, systemic and inhaled (the Open Study of Early Corticosteroid Treatment). Pediatrics 117 (2006) 2196-2205
58. de Vries W.B., Karemaker R., Mooy N.F., et al. Cardiovascular follow-up at school age after perinatal glucocorticoid exposure in prematurely born children: perinatal glucocorticoid therapy and cardiovascular follow-up. Arch Pediatr Adolesc Med 162 (2008) 738-744
59. Karemaker R., Karemaker JM., Kavelaars A., et al. Late effects of neonatal corticosteroid treatment on the cardiovascular stress response in children at school age. Pediatrics 122 (2008) 978-987
60. Huang C.C., Lin H.R., Liang Y.C., and Hsu K.S. Effects of neonatal corticosteroid treatment on hippocampal synaptic function. Pediatr Res 62 (2007) 267-270
61. De Kloet E.R., Vreugdenhil E., Oitzl M.S., and Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 19 (1998) 269-301
62. Sapolsky R.M., Uno H., Rebert C.S., and Finch C.E. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 10 (1990) 2897-2902
63. Uno H., Tarara R., Else J.G., Suleman M.A., and Sapolsky R.M. Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci 9 (1989) 1705-1711
64. Almeida O.F., Conde G.L., Crochemore C., et al. Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 14 (2000) 779-790
65. Holmes M.C., and Seckl J.R. The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol 248 (2006) 9-14
66. Holmes M.C., Sangra M., French K.L., et al. 11beta-Hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience 137 (2006) 865-873
67. Taketomo C.K. Pediatric dosage handbook. 11th ed. (2004), Lexicomp; Hudson, Ohio
68. Reist M., Marshall K.A., Jenner P., and Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. J Neurochem 71 (1998) 2431-2438
69. Baud O., Laudenbach V., Evrard P., and Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 50 (2001) 706-711
70. Kajanne R., Leppa S., Luukkainen P., et al. Hydrocortisone and indomethacin negatively modulate EGF-R signaling in human fetal intestine. Pediatr Res 62 (2007) 570-575
71. Caeymaex L., Gatel P., Castel C., Dehan M., and Zupan-Simunek V. Low-dose hydrocortisone alone does not lead to gastro-intestinal perforation in ELBW infants. SPR (2006) E-PAS2006: 2861
72. Ramanathan R., Siassi B., Sardesai S., and deLemos R. Dexamethasone versus hydrocortisone for hypotension refractory to high dose inotropic agents and incidence of candida infection in extremely low birth weight infants. Pediatr Res 39 (2006) 240A
73. Botas C.M., Kurlat I., Young S.M., and Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 95 (1995) 883-887